|Videos|May 30, 2023
CAR-T Cell Therapies Entering the Mainstream of Cancer Clinical Trials & Treatment
Author(s)Medidata
KEY LEARNING OBJECTIVES
- Audience will have an understanding how Medidata can have an impact with Clinical Trial pharma and bio tech firms that are working in this therapeutic area
- What are the challenges that CAR-T developers face and how can data help address those challenges
- How is Medidata AI “data” different from other data providers
Related Content
Trending on Applied Clinical Trials Online
1
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
2
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
3
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
4
HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research
5